Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Open-Label, Safety Study of Diclofenac [Test] Capsules in Subjects With Osteoarthritis of the Knee or Hip

Next Previous
Trial Profile

A Multicenter, Open-Label, Safety Study of Diclofenac [Test] Capsules in Subjects With Osteoarthritis of the Knee or Hip

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 22 Mar 2019

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Diclofenac (Primary)
  • Indications Musculoskeletal pain; Osteoarthritis
  • Focus Adverse reactions; Registrational
  • Sponsors Iroko Pharmaceuticals

Most Recent Events

  • 19 Nov 2014 Results presented at the 78th American College of Rheumatology and the 49th Annual Meeting of the Association of Rheumatology and Health Professionals.
  • 19 Nov 2014 Safety results presented at the 78th American College of Rheumatology and the 49th Annual Meeting of the Association of Rheumatology and Health Professionals.
  • 25 Aug 2014 Diclofenac [ZOROVOLEX] was approved by the US FDA for the management of osteoarthritis pain based on data from the parent trial and this safety extension study, according to an Iroko Pharmaceuticals media release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top